EMAIL DETAILS

The WGS is low pass.

(e.g. 4-10X)

Kenna R. Mills Shaw, Ph.D.
Executive Director
Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy (IPCT)
1400 Holcombe Blvd. | FC12.2002|Houston, TX 77030
• 713.792-1873 office; 713-792-6670 main; 713-792-6671 fax

From: Patrick Soon-Shiong [mailto:pss@nantworks.com]
Sent: Tuesday, March 10, 2015 9:41 AM
To: Yung,W K Alfred; Howard Krein; Mark Hyman; Steve Benz; Shahrooz Rabizadeh; Dan Kelly; Walter MD Urba; Santosh Kesari
Cc: Hunter Biden; Hallie Biden; Beau Biden; Kim Nicholson; Phil Yang; Marci Rodriguez; Shahrooz Rabizadeh; Mills,Gordon B; Hwu,Patrick; Chin,Lynda; Cassian Yee; Shaw,Kenna R; DePinho,Ronald A
Subject: Re: next steps

Thanks Alfred
The over-expressed peptides are of interest. Do you perform RNA -seq. On the previous frozen sample?
If not if we could receive the sample and we would be happy to do that. Also could we receive the file on the WGS....what depth of coverage was performed on the WGS‎?
Thanks for the update
Pat
PS. Adding some members of our team on the email trail

Sent from my BlackBerry 10 smartphone on the Verizon Wireless 4G LTE network.
From: Yung,W K Alfred
Sent: Monday, March 9, 2015 5:16 PM
To: Patrick Soon-Shiong; Howard Krein; Mark Hyman
Cc: Hunter Biden; Hallie Biden; Beau Biden; Kim Nicholson; Phil Yang; Marci Rodriguez; Shahrooz Rabizadeh; Mills,Gordon B; Hwu,Patrick; Chin,Lynda; Cassian Yee; Shaw,Kenna R; DePinho,Ronald A
Subject: Re: next steps


We have done deep molecular analysis on Beau's original tumor with our T200 panel and WGS. The profile is quite bland, not too many mutations is found, major GBM associated genes like EGFR, PTEN, PIK3CA, PDGFRA, HER2 are negative, only 2 positive hits: p53 and PTPN11. IHC showed increase pAKT, PDGFRA, pMAPK. Patrick's team have identified 10 over-expressed peptides for the preparation of an immuned-T-cell vaccine which we planned to use with the anti-PD1.
I certainly welcome any help we can get. We have planned to do another round of deep molecule analysis of the new tumor after it is removed next week.
Al


W. K. Alfred Yung, M.D.
Chair,Department of Neuro-Oncology
UT M.D. Anderson Cancer Center
1515 Holcombe Blvd.
Houston, TX 77030
713-794-1285


From: Patrick Soon-Shiong <pss@nantworks.com<mailto:pss@nantworks.com>>
Date: Monday, March 9, 2015 9:36 AM
To: Howard Krein <howard@startuphealth.com<mailto:howard@startuphealth.com>>, Mark Hyman <Mark@ultrawellnesscenter.com<mailto:Mark@ultrawellnesscenter.com>>
Cc: Hunter Biden <rhb@rspdc.com<mailto:rhb@rspdc.com>>, Hallie Beiden <halliebiden@gmail.com<mailto:halliebiden@gmail.com>>, Beau Biden <261penn@gmail.com<mailto:261penn@gmail.com>>, Alfred Yung <wyung@mdanderson.org<mailto:wyung@mdanderson.org>>, Kim Nicholson <Kim.Nicholson@swedish.org<mailto:Kim.Nicholson@swedish.org>>, Phil Yang <phil.yang@nantworks.com<mailto:phil.yang@nantworks.com>>, Marci Rodriguez <Marci.Rodriguez@nantworks.com<mailto:Marci.Rodriguez@nantworks.com>>, Shahrooz Rabizadeh <Shahrooz@nantworks.com<mailto:Shahrooz@nantworks.com>>
Subject: Re: next steps


Dear Howard and Mark
Happy to help in anyway we can. As a first step we should retieve the tissue (both the paraffin block and the fresh frozen) from the surgery performed a year ago. We could begin the panomic sequencing on that sample now and before the next surgery. We will look for eGfr and Her+ markers as potential targets for the NK92 treatment.


Kim will reach out to you today. Also will coordinate a call for Tuesday with our team to review all images to date


Keep well
Patrick
Sent from my BlackB
erry 10 smartphone on the Verizon Wireless 4G LTE network.
From: Howard Krein
Sent: Monday, March 9, 2015 5:36 AM
To: Mark Hyman
Cc: Hunter Biden; Hallie Biden; Beau Biden; Patrick Soon-Shiong; Al Yung MD
Subject: Re: next steps


Mark,
Thank you once again for arranging this. I had a conversation with Al last night and he is on board with everything. He is in Hong Kong till Thursday but will be available to do a call with Patrick Tuesday at 4 PM PST if that works. He also realizes the time constraints we are under and doesn't want to miss any potential opportunities. I can arrange a call in number if that works for Patrick.
Warmly,
Howard
Howard D. Krein MD, PhD
Assistant Professor
Div. of Facial Plastics and Reconstructive Surgery
Dept. of Otolaryngology/ Head and Surgery
Thomas Jefferson University
215-955-6760<tel:215-955-6760>

StartUp Health
Chief Medical Officer
Howard@startuphealth.com<mailto:Howard@startuphealth.com>

On Mar 9, 2015, at 1:41 AM, Mark Hyman <Mark@ultrawellnesscenter.com<mailto:Mark@ultrawellnesscenter.com>> wrote:
Dear All,

I am writing to connect everyone so Dr. Patrick can start the process of gaining access to records and set up integrated team meeting as the next step.
Thanks for all your time today and allowing us to be part of your care team.
I have also copied Dr. Yung so that he and Dr. Patrick can connect directly to expedite care coordination.

Be well,

Mark
------------------
Mark Hyman, MD
Director, Cleveland Clinic Center for Functional Medicine
Founder and Medical Director
The UltraWellness Center
Chairman, Institute for Functional Medicine
55 Pittsfield Road, Suite 9
Lenox Commons
Lenox, MA 01240
(413) 637-9991
mark@drhyman.com<mailto:mark@drhyman.com>
www.drhyman.com<http://www.drhyman.com>

Follow me:
Facebook<http://www.facebook.com/drmarkhyman>
Twitter<https://twitter.com/#!/markhymanmd>
Linked In<http://www.linkedin.com/in/drhyman>

Confidentiality Notice: This e-mail message and any attachments from The UltraWellness Center are confidential and for the sole use of the intended recipient. This communication may contain Protected Health Information (“PHI”). PHI is confidential information that may only be used or disclosed in accordance with applicable law. There are penalties under the law for the improper use or further disclosure of PHI. If you are not the intended recipient of this e-mail or the employee or agent responsible for delivering the communication to the intended recipient, then you may not read, copy, distribute or otherwise use or disclose the information contained in this message. If you received this message in error, please notify us by return email and delete this email from your system.
CONFIDENTIALITY NOTICE
This e-mail message and any attachments are only for the use of the intended recipient and may contain information that is privileged, confidential or exempt from disclosure under applicable law. If you are not the intended recipient, any disclosure, distribution or other use of this e-mail message or attachments is prohibited. If you have received this e-mail message in error, please delete and notify the sender immediately. Thank you